Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Top Cited Papers
- 1 June 2015
- journal article
- research article
- Published by Elsevier BV in Gastroenterology
- Vol. 148 (7), 1320-1329.e3
- https://doi.org/10.1053/j.gastro.2015.02.031
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Paradoxical inflammation induced by anti-TNF agents in patients with IBDNature Reviews Gastroenterology & Hepatology, 2012
- Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical TrialsClinical Therapeutics, 2011
- Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseasesArthritis Research & Therapy, 2011
- Population pharmacokinetic analysis of infliximab in patients with ulcerative colitisEuropean Journal of Clinical Pharmacology, 2009
- Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitisGut, 2009
- Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn’s DiseaseClinical Gastroenterology and Hepatology, 2006
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005
- Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2005
- Estimating mean QALYs in trial‐based cost‐effectiveness analysis: the importance of controlling for baseline utilityHealth Economics, 2004
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002